Lonza Group Ltd
LONN: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 827.00 | Bsdwyww | Fjxzbmr |
Lonza Earnings: Demand for Outsourced Manufacturing Remains Strong; Positive Long-Term Outlook
Lonza ended 2023 with solid sales of CHF 6.7 billion, representing growth of 7.9% year over year. Strong performance in the biologics and small molecules segments accounted for more than 70% of the company’s revenue and each segment delivered impressive margins of more than 30%. We maintain our fair value estimate of CHF 530 per share, and we view the stock as undervalued, currently trading in 4-star territory about 19% below our fair value estimate.